Eli Lilly upgraded at Bernstein As previously reported, Bernstein upgraded Eli Lilly to Outperform from Market Perform. The firm upgraded shares based on the increased likelihood that solanezumab will eventually make it to market in Alzheimer's disease, its pipeline opportunities, and potential upside if it were to win the Alimta patent challenge. Correct price target is $52, raised from $46.
News For LLY From The Last 14 Days
Check below for free stories on LLY the last two weeks.